CWP
SRPT icon

Concord Wealth Partners’s Sarepta Therapeutics SRPT Stock Holding History

Concord Wealth Partners’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10
Closed -$1.58K – 1019
2024
Q2 		$1.58K Buy
+10
New +$1.28K ﹤0.01% 680
2022
Q2 		– Sell
-1
Closed – – 1360
2022
Q1 		$0 Hold
1
– – ﹤0.01% 1378
2021
Q4 		$0 Buy
+1
New +$85 ﹤0.01% 1344

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Concord Wealth Partners's SRPT Position: Q3 2024 in Review

Concord Wealth Partners sold out of Sarepta Therapeutics (SRPT) in Q3 2024, closing a stake of 10 shares — an estimated $1.58K sold.

Concord Wealth Partners first reported a position in SRPT in Q4 2021 and held it in 3 quarters. The position peaked at $1.58K in Q2 2024. 457 funds tracked by Wall St. Rank hold SRPT as of Q3 2024.

  • Concord Wealth Partners reported no remaining Sarepta Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Concord Wealth Partners sold 10 Sarepta Therapeutics shares in Q3 2024, an estimated $1.58K.
  • Concord Wealth Partners first reported a position in Sarepta Therapeutics in Q4 2021 and held it in 3 quarters.
  • Concord Wealth Partners's Sarepta Therapeutics position peaked at $1.58K in Q2 2024.
  • 457 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2024.

Based on Concord Wealth Partners's 13F filing for Q3 2024, filed 24 Oct 2024.